Baseline Scans in DLBCL Patients Can Predict Response to CAR-T Therapy

Background: The assessment of disease status in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is essential to determine the most appropriate treatment. Anti-CD19 chimeric antigen receptor T (CAR-T) cell therapy is a newer method of treatment that has shown promising responses in this clinical scenario, but the prognosis for individual patients undergoing this treatment remains challenging. Objective: To determine whether [ 18 F]FDG PET/CT could provide accurate information about the prognosis in relapsed or refractory DLBCL. Design: Retrospective cohort study. Methods: Patients with relapsed or refractory DLBCL were included. [ 18 F]FDG PET/CT scans on these patients were acquired before CAR-T, approximately 30 days after CAR-T, and approximately 135 days after CAR-T. The [ 18 F]FDG PET/CT protocol included body weight–based dosage of [ 18 F]FDG of 3 MBq/kg and acquisition approximately 1 hour after [ 18 F]FDG injection. PET/CT images were reviewed more...